Occult Bone Metastases From Hepatocellular Carcinoma Detected on 68Ga-PMSA PET/CT

Sharjeel Usmani 1, Rashid Rasheed 1, Fareeda Al Kandari 1, Najeeb Ahmed 2

Affiliations

01 August 2021

-

doi: 10.1097/RLU.0000000000003515

Abstract

68Ga-PSMA is an excellent radiotracer for both staging and detection of recurrence in prostate cancer, but it can also be useful in other solid tumors due to tumor-associated angiogenic factors and endothelial cell sprouting. We report a case of an 82-year-old man with hepatocellular carcinoma who presented with rising tumor marker but stable CT findings 6 months after transarterial chemoembolization. 68Ga-PSMA PET/CT showed high PSMA-expressing hyperneovascular hepatic lesions (primary tumor), additional multifocal hepatic lesions, and with unexpected multiple bone metastases. 68Ga-PSMA expression in hepatocellular carcinoma can influence patient management and potentially guide radionuclide legend therapy.

Conflict of interest statement

Conflicts of interest and sources of funding: none declared.

Similar articles

68Ga-PSMA Uptake in Combined Hepatocellular Cholangiocarcinoma With Skeletal Metastases.

Alipour R, Gupta S, Trethewey S.Clin Nucl Med. 2017 Oct;42(10):e452-e453. doi: 10.1097/RLU.0000000000001771.PMID: 28806238

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.PMID: 30843003

68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.

Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, Bäuerle T.Ann Nucl Med. 2019 Oct;33(10):766-775. doi: 10.1007/s12149-019-01387-0. Epub 2019 Jul 23.PMID: 31338731

The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.

Eissa A, Elsherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, Patel VR, Prandini N, Micali S, Sighinolfi MC, Puliatti S, Rocco B, Bianchi G.Minerva Urol Nefrol. 2018 Oct;70(5):462-478. doi: 10.23736/S0393-2249.18.03081-3. Epub 2018 Apr 17.PMID: 29664244 Review.

PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications.

Giovacchini G, Giovannini E, Riondato M, Ciarmiello A.Curr Radiopharm. 2018;11(1):4-13. doi: 10.2174/1874471010666171101121803.PMID: 29090673 Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926–937.
  2.  
    1. Usmani S, Sadeq A, Marafi F, et al. 68Ga-PMSA uptake in the lung: metastatic versus primary lung tumor. Clin Nucl Med. 2020;45:e80–e82.
  3.  
    1. Demirci E, Ocak M, Kabasakal L, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461–1462.
  4.  
    1. Sasikumar A, Joy A, Nanabala R, et al. 68Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:795–796.
  5.  
    1. Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006;26:5310–5324.
  6.  
    1. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–3198.
  7.  
    1. Kesler M, Levine C, Hershkovitz D, et al. 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med. 2019;60:185–191.
  8.  
    1. Taneja S, Taneja R, Kashyap V, et al. 68Ga-PSMA uptake in hepatocellular carcinoma. Clin Nucl Med. 2017;42:e69–e70.
  9.  
    1. Tolkach Y, Goltz D, Kremer A, et al. Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging. Oncotarget. 2019;10:4149–4160.
  10.  
    1. Zacho HD, Nielsen JB, Haberkorn U, et al. 68Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. Clin Physiol Funct Imaging. 2017.
  11.  
    1. Zacho HD, Ravn S, Afshar-Oromieh A, et al. Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy. EJNMMI Res. 2020;10:31.
  12.  
    1. Rahbar K, Bode A, Weckesser M, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41:522–528.

Page Navigation